US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATS Corp.

25.53

+0.23000.91%

Pre-market: 25.42-0.1100-0.43%05:15 EDT

Volume:84.76K

Turnover:2.16M

Market Cap:2.50B

PE:40.73

High:25.91

Open:25.31

Low:25.23

Close:25.30

Loading ...

Overview Company News Filings

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Celestica Announces First Quarter 2025 Financial Results

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

ICE Bonds Enhances MBS Trading With New RFQ Protocol on ICE TMC Platform

SkyWater Appoints Dr. Percy Gilbert as Senior Vice President of Engineering

Press Release: Securitize Acquires MG Stover's Fund Administration Business to Become the Largest Digital Asset Fund Administrator

ParaZero Launches SafeAir M4 – Its Most Advanced Parachute Recovery System, Now Compatible with DJI Matrice 4

ATS Corporation to Engage with Investors at RBC Capital Markets Conference

ATS to Participate in the RBC Capital Markets Canadian Industrials Conference

AI might be scanning your resume. Here’s what job hunters should know

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Is Now An Opportune Moment To Examine ATS Corporation (TSE:ATS)?

Simply Wall St.

Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference

OTC Markets Group Welcomes Credit Corp Group Ltd. to OTCQX

Press Release: MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Darker Than a Dark Pool? Welcome to Wall Street’s ‘Private Rooms’

High Growth Tech Stocks to Watch in March 2025

Simply Wall St.

Press Release: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATS\",,,,,undefined,":{"symbol":"ATS","market":"US","secType":"STK","nameCN":"ATS Corp.","latestPrice":25.53,"timestamp":1745870400000,"preClose":25.3,"halted":0,"volume":84761,"hourTrading":{"tag":"盘前","latestPrice":25.42,"preClose":25.53,"latestTime":"05:15 EDT","volume":104,"amount":2631.7197920000003,"timestamp":1745918122317},"delay":0,"floatShares":81570898,"shares":97928315,"eps":0.626793,"marketStatus":"Pre-Mkt","change":0.23,"latestTime":"04-29 09:17:49 EDT","open":25.31,"high":25.91,"low":25.23,"amount":2161515.265495,"amplitude":0.026877,"askPrice":31,"askSize":100,"bidPrice":7.36,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.626793,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745933400000},"marketStatusCode":1,"adr":0,"listingDate":1684987200000,"exchange":"NYSE","adjPreClose":25.53,"preHourTrading":{"tag":"盘前","latestPrice":25.42,"preClose":25.53,"latestTime":"05:15 EDT","volume":104,"amount":2631.7197920000003,"timestamp":1745918122317},"postHourTrading":{"tag":"盘后","latestPrice":25.53,"preClose":25.53,"latestTime":"16:43 EDT","volume":14574,"amount":372433.887776,"timestamp":1745872996326},"volumeRatio":0.6778699979305687,"impliedVol":0.2613,"impliedVolPercentile":0.1406},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATS\",,,,,undefined,":{"symbol":"ATS","floatShares":81570898,"roa":"3.37%","roe":"5.30%","lyrEps":1.463463,"volumeRatio":0.6778699979305687,"shares":97928315,"dividePrice":0,"high":25.91,"amplitude":0.026877,"preClose":25.3,"low":25.23,"week52Low":20.9,"pbRate":"1.97","psRate":"1.26","week52High":35.415,"institutionHeld":0,"latestPrice":25.53,"eps":0.626793,"divideRate":0,"volume":84761,"delay":0,"ttmEps":0.626793,"open":25.31,"prevYearClose":30.48,"prevWeekClose":25.3,"prevMonthClose":24.93,"prevQuarterClose":24.93,"fiveDayClose":23.53,"twentyDayClose":25.92,"sixtyDayClose":27.26},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530472503","title":"Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472503","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472503?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April 28, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,today announced that an abstract has been accepted at the American Thoracic Society  2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.Details of the poster presentation are as follows:. Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides  in Three Dimensional  Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and FibrosisDate & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET. Rein Investor Relations & Media Contact:Argot Partnersrein@argotpartners.com 212-600-1902","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","BK4007","BK4139","AFG","RNTX","BK4117","LENZ","CSD","ATS","BK4161"],"gpt_icon":0},{"id":"2530995847","title":"Celestica Announces First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530995847","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530995847?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:15","pubTimestamp":1745525700,"startTime":"0","endTime":"0","summary":"Q1 2025 revenue and adjusted EPS* above the high end of our guidance ranges;Raising 2025 annual outlook. TORONTO, April 24, 2025  -- Celestica Inc.  , a leader in design, manufacturing, hardware platform and supply chain solutions for the world's most innovative companies, today announced financial results for the quarter ended March31, 2025 .Adjusted operating margin *: 7.1%, compared to 5.9% for Q1 2024.“Celestica delivered a strong first quarter in 2025, achieving revenue of $2.65 billion and non-GAAP adjusted EPS* of $1.20, both surpassing the high end of our guidance ranges. This strong performance was further highlighted by our highest ever adjusted operating margin* of 7.1%,” stated Rob Mionis, President and CEO.“With these results, and a strengthening demand outlook from our CCS customers, we are raising our full-year 2025 outlook. We now expect revenue to reach $10.85 billion, an increase from our prior $10.7 billion, and anticipate non-GAAP adjusted EPS* of $5.00, up from our","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celestica-announces-first-quarter-2025-201500873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4126","BK4088","BK4145","SBC","BK4196","LU2045819591.USD","LU0128526141.USD","LU2125910500.SGD","ATS","CCS","BK4161","LU0029874061.USD","BK4585","CLS","TRS"],"gpt_icon":0},{"id":"2529874081","title":"United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874081","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874081?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:00","pubTimestamp":1745233200,"startTime":"0","endTime":"0","summary":"Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium. An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session. SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 21, 2025----United Therapeutics Corporation , a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society  International Conference in San Francisco on May 16-21, 2025.At ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the ATS Research Program Benefit Networking Event, and the company is hosting the Jenesis Innovative Research Awards Ceremony.Thematic poster session. Sunday, May 18, 11:30 a.m. to 1:15 p.m. PT: A48/P1624 – TETON Phase 3 Clinical Trials of Inhaled Treprosti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/united-therapeutics-feature-clinical-data-110000565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU1699723380.USD","BK4117","BK4107","LU1571399168.USD","PT","BK4139","ATS","PBC","BK4161","UTHR","AFG","BK4166"],"gpt_icon":0},{"id":"2527211240","title":"GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2527211240","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527211240?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:35","pubTimestamp":1744806900,"startTime":"0","endTime":"0","summary":"LA JOLLA, CA, April 16, 2025  -- GRI Bio, Inc.  , a biotechnology company advancing an innovative pipeline of Natural Killer T  cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ATS International Conference being held May 18-21, 2025 in San Francisco, CA.Details of the presentation are as follows:Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary FibrosisPoster Board Number: 810Presenter: Marc Hertz, PhD, Chief Executive Officer of GRI BioSession: D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIRDate and Time: Wednesday, May 21, 2025 from 8:15-10:15 AM PTLocation: Room 2022/2024 , Moscone CenterFor more information about the 2025 ATS International Conference, please visit the conference website, here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gri-bio-announces-abstract-selected-123500260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","GRI","ATS","BK4139","BK4117","BK4107","BK4007"],"gpt_icon":0},{"id":"2527240854","title":"ICE Bonds Enhances MBS Trading With New RFQ Protocol on ICE TMC Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2527240854","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527240854?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:30","pubTimestamp":1744806600,"startTime":"0","endTime":"0","summary":"New RFQ Protocol provides enhanced liquidity, flexibility and efficiency for MBS trading. NEW YORK & ATLANTA, April 16, 2025----ICE Bonds, part of Intercontinental Exchange , a leading global provider of technology and data, today announced the launch of a new Request-for-Quote  protocol for Mortgage-Backed Securities . This new functionality sits alongside ICE Bonds’ existing MBS Click-to-Trade marketplace and allows clients to send MBS RFQs within ICE TMC’s anonymous trading pool.The ICE TMC platform now offers an enhanced suite of execution capabilities for MBS trading, providing wealth management and retail brokerage clients with a more flexible and efficient trading environment. This new RFQ feature complements the platform’s existing Click-to-Trade functionality, driving increased liquidity and execution efficiency in the MBS market.\"The addition of RFQ trading meaningfully enhances our MBS offering, expanding the ways our clients can access liquidity and engage with the market,\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ice-bonds-enhances-mbs-trading-123000800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0417517546.SGD","LU0154245673.USD","LU2237957902.USD","LU1201861249.SGD","LU1153585028.USD","LU0949170772.SGD","SGXZ23171101.USD","LU2023250504.SGD","LU2023250843.SGD","KIDS","LU0154245756.USD","MBS","LU0648001328.SGD","SG9999004303.SGD","LU0738911758.USD","BK4168","LU0477156953.USD","LU0256863811.USD","LU1974910355.USD","LU0661504455.SGD","LU0124676726.USD","ICE","BK4112","LU0980610538.SGD","LU0154236417.USD","GB00BDT5M118.USD","LU0256863902.USD","LU0689626769.HKD","LU1917777945.USD","BK4588","LU2237957811.SGD","LU0130517989.USD","IE00BQXX3D17.EUR","LU0390134368.USD","LU0011850046.USD","ATS","BK4161","BK4198","LU0130102774.USD","LU2106854487.HKD","BK4563","IE00BQXX3F31.USD","IE00BQXX3C00.GBP"],"gpt_icon":1},{"id":"2527211792","title":"SkyWater Appoints Dr. Percy Gilbert as Senior Vice President of Engineering","url":"https://stock-news.laohu8.com/highlight/detail?id=2527211792","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527211792?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:05","pubTimestamp":1744801500,"startTime":"0","endTime":"0","summary":"Gilbert’s extensive technical expertise, proven track record of accomplishments and dedication to R&D underscore his proficiency in advanced semiconductor technologies. BLOOMINGTON, Minn., April 16, 2025----SkyWater Technology , the trusted technology realization partner, today announced the appointment of Dr. Percy V. Gilbert as senior vice president of engineering. Gilbert will report directly to President and COO John Sakamoto and will be responsible for leading and expanding SkyWater’s engineering organization, which is integral to the company’s ongoing strategic growth in Advanced Technology Services , platform solutions and Wafer Services .\"The appointment of Percy to lead our engineering team represents a significant milestone for SkyWater,\" said Sakamoto. \"His leadership and technical expertise will drive our innovative culture as we continue to scale our operations and enhance our engineering capabilities. We look forward to leveraging his vast experience in semiconductor tech","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skywater-appoints-dr-percy-gilbert-110500698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATS","BK4161","BK4006","WS","BK4141","BK4539","SKYT"],"gpt_icon":0},{"id":"2527442089","title":"Press Release: Securitize Acquires MG Stover's Fund Administration Business to Become the Largest Digital Asset Fund Administrator","url":"https://stock-news.laohu8.com/highlight/detail?id=2527442089","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527442089?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:23","pubTimestamp":1744748580,"startTime":"0","endTime":"0","summary":"Securitize Fund Services now administers over $38 billion in assets across 715 funds. MIAMI, April 15, 2025 /PRNewswire/ -- Securitize, the leading platform for real-world asset tokenization, has announced the acquisition of MG Stover's Fund Administration business, the pioneering fund administration firm for digital assets. With this acquisition, Securitize's subsidiary, Securitize Fund Services , becomes the world's largest digital asset fund administrator.This acquisition significantly expands SFS, enhancing its ability to provide best-in-class fund administration, compliance, and reporting solutions to institutional-grade asset issuers and investors, while seamlessly integrating with Securitize's broader offerings, including a broker-dealer and digital transfer agent capabilities, tokenization platform, operator of an alternative trading system , and digital asset management.As of Monday April 14, 2025*, Securitize has issued $3.3B+ in assets on-chain, including:. Securitize, the l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","IE00B66KJ199.SGD","IE0031619046.USD","ATS","MG","IE00B19Z4B17.USD","BK4161","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2527492058","title":"ParaZero Launches SafeAir M4 – Its Most Advanced Parachute Recovery System, Now Compatible with DJI Matrice 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492058","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492058?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:25","pubTimestamp":1744716300,"startTime":"0","endTime":"0","summary":"New generation of parachute technology combines a completely new design, swappable parachute capsules and triple sensor redundancy to redefine drone safety. TEL AVIV, Israel, April 15, 2025  -- ParaZero Technologies Ltd.  , an aerospace company focused on safety systems for commercial unmanned aerial systems and counter UAS systems, today announced the launch of its latest drone safety innovation – theSafeAir M4, its next-generation autonomous parachute recovery system now fully compatible with the DJI Matrice 4 series.The SafeAir M4 represents the most advanced version of ParaZero’s proven SafeAir system, incorporating aircraft-grade technology, a newly developed airbag-based deployment mechanism, plug-and-play design, and multi-layered compliance with both U.S. and European aviation regulations.“The launch of the SafeAir M4 marks a strategic milestone in ParaZero’s efforts to lead the global drone safety market,” added Boaz Shetzer, CEO of ParaZero. “As drone operations scale across ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/parazero-launches-safeair-m4-most-112500399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FTS","IE00B7SZL793.SGD","AEIS","BK4161","BK4603","ATS","IE0031619046.USD","IE00B66KJ199.SGD","BK4157","BK4532","PRZO","IE00B19Z4B17.USD","BK4081"],"gpt_icon":0},{"id":"2527140284","title":"ATS Corporation to Engage with Investors at RBC Capital Markets Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2527140284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527140284?lang=en_us&edition=fundamental","pubTime":"2025-04-15 05:39","pubTimestamp":1744666749,"startTime":"0","endTime":"0","summary":"ATS Corporation ( ($TSE:ATS) ) has provided an announcement. ATS Corporation announced that its Chief Financial Officer, Ryan McLeod, will particip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ats-corporation-to-engage-with-investors-at-rbc-capital-markets-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ats-corporation-to-engage-with-investors-at-rbc-capital-markets-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS","ISBC","BK4161","BK4211","BK4207"],"gpt_icon":0},{"id":"2527169147","title":"ATS to Participate in the RBC Capital Markets Canadian Industrials Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2527169147","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527169147?lang=en_us&edition=fundamental","pubTime":"2025-04-15 05:01","pubTimestamp":1744664460,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Ontario, April 14, 2025----ATS Corporation   today announced that Ryan McLeod, Chief Financial Officer will participate in the RBC Capital Markets Canadian Industrials Conference in Toronto on May 15, 2025.Management will host institutional investor meetings at the Conference, which can be arranged by contacting your RBC Capital Markets representative or dgalison@atsautomation.com.For general media inquiries, contact: Matthew RobinsonDirector, Corporate Affairs & CommunicationATS Corporation730 Fountain Street NorthCambridge, ON, N3H 4R7 653-6500mrobinson@atsautomation.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ats-participate-rbc-capital-markets-210100305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATS","BK4161","BK4207"],"gpt_icon":0},{"id":"2526848299","title":"AI might be scanning your resume. Here’s what job hunters should know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526848299","media":"CNN Business","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526848299?lang=en_us&edition=fundamental","pubTime":"2025-04-08 22:00","pubTimestamp":1744120838,"startTime":"0","endTime":"0","summary":"A human resources representative or hiring manager may not be the first to review your resume. Instead, it might be an AI-powered tool.With some job postings attracting hundreds or thousands of applications, companies are increasingly using AI to sort through applicants before they reach a human recruiter. According to data from jobseeker resource site Resume Genius, 48% of hiring managers report using AI to screen resumes and applications, and the AI recruitment sector is expected to experience a compound annual growth rate of 6.1% between 2023 and 2030, according to the Society for Human Resources Management.While companies have long been using applicant tracking systems  to parse resumes for skills and keywords, AI has the potential to further automate the process by “reading” resumes and applications to find suitable candidates.But can that make it more difficult to guarantee a resume gets seen by a human?Experts say AI can benefit both recruiters and candidates by allowing applica","market":"hk","thumbnail":"https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1357880678.jpg?c=16x9&q=h_144,w_256,c_fill","type":0,"news_type":0,"thumbnails":["https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1357880678.jpg?c=16x9&q=h_144,w_256,c_fill"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://edition.cnn.com/2025/04/08/tech/ai-resume-job-hunters/index.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cnn_highlight","symbols":["BK4161","ATS"],"gpt_icon":0},{"id":"2525076694","title":"Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2525076694","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525076694?lang=en_us&edition=fundamental","pubTime":"2025-04-08 04:05","pubTimestamp":1744056300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April  07, 2025  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3057198/0/en/Pliant-Therapeutics-Announces-Upcoming-Presentations-at-the-2025-American-Thoracic-Society-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4007","BK4107","BK4161","LENZ","BK4117","BK4139","ATS"],"gpt_icon":0},{"id":"2524923779","title":"Is Now An Opportune Moment To Examine ATS Corporation (TSE:ATS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524923779","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524923779?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:41","pubTimestamp":1743676915,"startTime":"0","endTime":"0","summary":"ATS Corporation , might not be a large cap stock, but it received a lot of attention from a substantial price movement on the TSX over the last few months, increasing to CA$44.75 at one point, and dropping to the lows of CA$35.87. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether ATS' current trading price of CA$37.52 reflective of the actual value of the mid-cap?Or is it currently undervalued, providing us with the opportunity to buy?Let’s take a look at ATS’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/now-opportune-moment-examine-ats-104155715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSE","ATS","BK4161","BK4090"],"gpt_icon":0},{"id":"2522724903","title":"Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2522724903","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522724903?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"- Data from the ASCENT study of LIQ861  in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life. - Case study highlights the long-term safety and tolerability of LIQ861  in a PAH patient transitioning from parenteral treprostinil in INSPIRE study. MORRISVILLE, N.C., March 27, 2025  -- Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,today announced the company will present three posters at the AmericanThoracic Society  2025 International Conference, taking placeMay 18-21, 2025, inSan Francisco. Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861  in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk distance, quality of life, and changes in cardiac effort. A third poster is a case study of a patient with PAH participating in the open-label extension stu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/liquidia-announces-poster-presentations-american-120000468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","AFG","BK4117","ATS","BK4107","BK4161","LQDA"],"gpt_icon":0},{"id":"2522760223","title":"OTC Markets Group Welcomes Credit Corp Group Ltd. to OTCQX","url":"https://stock-news.laohu8.com/highlight/detail?id=2522760223","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522760223?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 27, 2025  -- OTC Markets Group Inc. , operator of regulated markets for trading 12,000 U.S. and international securities, today announced Credit Corp Group Ltd. , Australia's largest provider of responsible financial services to the credit-impaired consumer segment, has qualified to trade on the OTCQX Best Market. Credit Corp Group Ltd. upgraded to OTCQX from the Pink market.Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.Media Contact:OTC Markets Group Inc., +1  896-4428, media@otcmarkets.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/otc-markets-group-welcomes-credit-110000126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CCGFF","CCP.AU","BK4161","BK7093","OTCM","ATS","BK4112","BK4166"],"gpt_icon":0},{"id":"2520297836","title":"Press Release: MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2520297836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520297836?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:30","pubTimestamp":1742297400,"startTime":"0","endTime":"0","summary":"NEW YORK, March 18, 2025  -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T  cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET.\"Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders,\" said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. \"We made significant clinical strides, strengthened our manufacturing foundation, and forged strategic alliances. Through disciplined capital management, we are positioned to scale efficiently and seize new collaboration opportunities for value creation. With our rapid AI-driven drug discovery platform generating a world-class l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","ARDS","ATS","INKT","BK4139","PRGS","LENZ","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2520520888","title":"Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520520888","media":"Business Wire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520520888?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:05","pubTimestamp":1742213100,"startTime":"0","endTime":"0","summary":"-- Company to Host Industry Theater on aPAP with Two World-Renowned Experts --. LANGHORNE, Pa., March 17, 2025----Savara Inc.  , a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society  International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled \"Advances in Autoimmune Pulmonary Alveolar Proteinosis \" at the meeting.The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine on May 1, 2025. For more details about the ATS International Conference please visit their website.aPAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-present-data-phase-3-120500851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4139","BK4161","BK4117","ATS","SVRA","BK4107"],"gpt_icon":0},{"id":"2520458109","title":"Darker Than a Dark Pool? Welcome to Wall Street’s ‘Private Rooms’","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458109","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458109?lang=en_us&edition=fundamental","pubTime":"2025-03-17 05:51","pubTimestamp":1742161885,"startTime":"0","endTime":"0","summary":"A new kind of gated stock venue is emerging amid the historic shift of trading away from US public exchanges.","market":"us","thumbnail":"https://www.bnnbloomberg.ca/resizer/v2/KYWSFXPA4X4AXIDWEPH4EXL7JA.jpg?smart=true&auth=99435a45fa75253cb9b6be44491e344bc4bd08fb00090d3de06665a92c866ec8&width=500&height=333","type":0,"news_type":0,"thumbnails":["https://www.bnnbloomberg.ca/resizer/v2/KYWSFXPA4X4AXIDWEPH4EXL7JA.jpg?smart=true&auth=99435a45fa75253cb9b6be44491e344bc4bd08fb00090d3de06665a92c866ec8&width=500&height=333"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/business/company-news/2025/03/16/darker-than-a-dark-pool-welcome-to-wall-streets-private-rooms/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["LU1564329032.USD","LU2063271972.USD","LU0466842654.USD","IE00B5949003.HKD","LU2505996681.GBP","LU1074936037.SGD","IE0005OL40V9.USD","LU1435385759.SGD","LU0444973449.USD","LU0738911758.USD","LU0006306889.USD","LU1489326972.SGD","IE00B19Z3581.USD","LU2360106780.USD","LU0154236417.USD","IE0004445015.USD","BK4587","IE00B19Z8X17.USD","IE00BJTD4N35.SGD","IE00BQXX3D17.EUR","IE00BJTD4V19.USD","SG9999014880.SGD","LU0234572021.USD","LU0786609619.USD","LU1261432733.SGD","LU1548497426.USD","LU0109391861.USD","LU0345769631.USD","POOL","LU0320765059.SGD","LU2720916845.USD","IE00B1XK9C88.USD","LU2054465674.USD","SG9999014906.USD","LU0820562030.AUD","IE00B19Z3B42.SGD","LU2430703178.SGD","BK4543","LU0433182093.SGD","LU0985320562.USD","IE00BKDWB100.SGD","LU0949170772.SGD","LU1670710661.SGD","LU0308772762.SGD","IE00B1BXHZ80.USD","LU2023250504.SGD","ATS","LU0444971666.USD","SG9999014914.USD"],"gpt_icon":1},{"id":"2519207148","title":"High Growth Tech Stocks to Watch in March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2519207148","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519207148?lang=en_us&edition=fundamental","pubTime":"2025-03-14 17:08","pubTimestamp":1741943294,"startTime":"0","endTime":"0","summary":"As global markets grapple with trade policy uncertainties and inflation concerns, U.S. stocks have faced significant declines, with major indices like the S&P 500 and Nasdaq Composite experiencing notable drops. Amid this volatility, investors often look for high-growth tech stocks that demonstrate resilience through innovation and adaptability to navigate such challenging economic landscapes effectively.Operations: Wantai focuses on the research, development, production, and sale of biological diagnostic products and vaccines. It operates with a market cap of CN84.51 billion.Overview: Chongqing Zhifei Biological Products Co., Ltd. is a company engaged in the research, development, production, and sales of vaccines and other biological products with a market cap of CN59.13 billion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-090814853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU2045819591.USD","LU2125910500.SGD","CCS","BK4088","ATS","BK4145","BK4161","BK4588","CLS"],"gpt_icon":1},{"id":"2519866726","title":"Press Release: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519866726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519866726?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:01","pubTimestamp":1741896060,"startTime":"0","endTime":"0","summary":"Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces its favorable safety profile.\"2024 was an important year for aTyr, as we completed enrollment in our global pivotal Phase 3 EFZO-FIT study, which is the largest interventional study ever to be conducted in pulmonary sarcoidosis, a disease where incidence and prevalence are rising yet there are still limited treatment options,\" said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. \"The stage is set for 2025 to be a potential milestone year as we look toward reporting topline data for EFZO-FIT in the third quarter. Leading into this pivotal readout, we are very pleased with the execution of the study to date and the continued favorable safety profile demonstrated for efzofitimod, including our most recent positive DSMB review, which recommended the study continue ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4528","BK4139","BK4099","BK4555","BK4023","BK4588","ATS","ATYR","SAP","BK4585","BK4161","03160","BK4604","TM","BK4613"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":115,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-05","symbol":"ATS","fiscalQuarterEnding":"2024/12","expectedEps":0.23,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738731600000,"reportTimeType":"pre","actualEps":0.23},{"market":"US","date":"2024-11-06","symbol":"ATS","fiscalQuarterEnding":"2024/09","expectedEps":0.25,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"pre","actualEps":0.18},{"market":"US","date":"2024-08-08","symbol":"ATS","fiscalQuarterEnding":"2024/06","expectedEps":0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":0.37},{"market":"US","date":"2024-05-16","symbol":"ATS","fiscalQuarterEnding":"2024/03","expectedEps":0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715832000000,"reportTimeType":"pre","actualEps":0.48},{"market":"US","date":"2024-02-07","symbol":"ATS","fiscalQuarterEnding":"2023/12","expectedEps":0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1707282000000,"reportTimeType":"pre","actualEps":0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8571,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8571,"analysts":7,"updateTime":1718424000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATS","date":"2025-04-25","current":38.011562,"percent":0.69469,"low":18.278787,"twenty":22.933896,"median":33.415912,"eighty":42.72692,"high":49.784492,"avg":33.042516,"sd":8.8727,"marketCap":2443342344.25},"quantilePoints":[{"date":"2023-06-02","current":46.343344,"twenty":46.194425,"median":46.266425,"eighty":46.306886,"marketCap":4385290976.46},{"date":"2023-06-09","current":46.009827,"twenty":46.17581,"median":46.28258,"eighty":46.915752,"marketCap":4390539453.8},{"date":"2023-06-16","current":45.438012,"twenty":45.320112,"median":46.164952,"eighty":46.476751,"marketCap":4375388926.84},{"date":"2023-06-23","current":48.145057,"twenty":45.487654,"median":46.266425,"eighty":47.860268,"marketCap":4658766213.85},{"date":"2023-06-30","current":46.896248,"twenty":45.651659,"median":46.266425,"eighty":47.485058,"marketCap":4511580364.18},{"date":"2023-07-07","current":46.270844,"twenty":46.009827,"median":46.312962,"eighty":47.5378,"marketCap":4411747145.22},{"date":"2023-07-14","current":48.698172,"twenty":46.043025,"median":46.511353,"eighty":47.780498,"marketCap":4728914205.59},{"date":"2023-07-21","current":48.480908,"twenty":46.105078,"median":46.872979,"eighty":48.286922,"marketCap":4686318579.71},{"date":"2023-07-28","current":45.850462,"twenty":46.043025,"median":46.851428,"eighty":48.286922,"marketCap":4428020690.86},{"date":"2023-08-04","current":44.368411,"twenty":46.009827,"median":46.763285,"eighty":48.152813,"marketCap":4237745227.85},{"date":"2023-08-11","current":42.700705,"twenty":45.438012,"median":46.511353,"eighty":48.145057,"marketCap":4326916372.16},{"date":"2023-08-18","current":40.050115,"twenty":44.926078,"median":46.32649,"eighty":48.075247,"marketCap":4021626143.41},{"date":"2023-08-25","current":41.899702,"twenty":43.443089,"median":46.270844,"eighty":48.061899,"marketCap":4194356348.69},{"date":"2023-08-31","current":43.312379,"twenty":42.678859,"median":46.219245,"eighty":47.836778,"marketCap":4344740041.37},{"date":"2023-09-08","current":43.843953,"twenty":42.897314,"median":46.105078,"eighty":47.634879,"marketCap":4353234860.78},{"date":"2023-09-15","current":43.042951,"twenty":42.657014,"median":45.930144,"eighty":47.433983,"marketCap":4325894000.62},{"date":"2023-09-22","current":41.921548,"twenty":42.559437,"median":45.562117,"eighty":47.311701,"marketCap":4220969734.92},{"date":"2023-09-29","current":42.533222,"twenty":42.508464,"median":45.081733,"eighty":47.274981,"marketCap":4280367687.17},{"date":"2023-10-06","current":40.050115,"twenty":42.428364,"median":44.926078,"eighty":47.160162,"marketCap":3958860964.51},{"date":"2023-10-13","current":39.423877,"twenty":42.00893,"median":44.615828,"eighty":47.035061,"marketCap":3917634187.34},{"date":"2023-10-20","current":36.088795,"twenty":41.126371,"median":44.229891,"eighty":46.935301,"marketCap":3572025991.12},{"date":"2023-10-27","current":34.661554,"twenty":40.778231,"median":44.058847,"eighty":46.909266,"marketCap":3403618402.31},{"date":"2023-11-03","current":33.358105,"twenty":40.050115,"median":43.843953,"eighty":46.860392,"marketCap":3284508208.07},{"date":"2023-11-10","current":31.05346,"twenty":39.978754,"median":43.47968,"eighty":46.850053,"marketCap":3541182846.54},{"date":"2023-11-17","current":33.712074,"twenty":39.645245,"median":43.312379,"eighty":46.711431,"marketCap":3845894896.75},{"date":"2023-11-24","current":33.592349,"twenty":38.190334,"median":43.072078,"eighty":46.623309,"marketCap":3848769791.51},{"date":"2023-12-01","current":33.655362,"twenty":35.166914,"median":42.886392,"eighty":46.541855,"marketCap":3891785593.98},{"date":"2023-12-08","current":33.604952,"twenty":34.322082,"median":42.591477,"eighty":46.44537,"marketCap":3879525100.59},{"date":"2023-12-15","current":35.923838,"twenty":34.218738,"median":42.507736,"eighty":46.366559,"marketCap":4204253502},{"date":"2023-12-22","current":36.07507,"twenty":34.272496,"median":42.474968,"eighty":46.323119,"marketCap":4257700834.69},{"date":"2023-12-29","current":36.289315,"twenty":34.310293,"median":42.423994,"eighty":46.304224,"marketCap":4315633982.44},{"date":"2024-01-05","current":34.650971,"twenty":34.327977,"median":42.161849,"eighty":46.287991,"marketCap":4072504954.25},{"date":"2024-01-12","current":35.442932,"twenty":34.397952,"median":41.910625,"eighty":46.273191,"marketCap":4139113955.77},{"date":"2024-01-19","current":36.274955,"twenty":34.423844,"median":41.655761,"eighty":46.2585,"marketCap":4216951441.35},{"date":"2024-01-26","current":36.917882,"twenty":34.562753,"median":40.778299,"eighty":46.231655,"marketCap":4292072985.19},{"date":"2024-02-02","current":36.987217,"twenty":34.654752,"median":40.235802,"eighty":46.154093,"marketCap":4330447033.68},{"date":"2024-02-09","current":31.2472,"twenty":34.423844,"median":40.050115,"eighty":46.10731,"marketCap":4053209917.9},{"date":"2024-02-16","current":29.911027,"twenty":34.218738,"median":40.010065,"eighty":46.067846,"marketCap":3869003534.07},{"date":"2024-02-23","current":28.569192,"twenty":34.062459,"median":39.908119,"eighty":46.029746,"marketCap":3697982548.6},{"date":"2024-03-01","current":28.954191,"twenty":33.729718,"median":39.700587,"eighty":45.946081,"marketCap":3727658474.68},{"date":"2024-03-08","current":28.897573,"twenty":33.622723,"median":38.630157,"eighty":45.760452,"marketCap":3749905081.21},{"date":"2024-03-15","current":28.33706,"twenty":33.535637,"median":37.535596,"eighty":45.60011,"marketCap":3663186667.6},{"date":"2024-03-22","current":28.378306,"twenty":33.360741,"median":37.125888,"eighty":45.512475,"marketCap":3664397837.7},{"date":"2024-03-28","current":27.463826,"twenty":33.187804,"median":36.956482,"eighty":45.379062,"marketCap":3545999564.77},{"date":"2024-04-05","current":25.261057,"twenty":31.829239,"median":36.880063,"eighty":45.11865,"marketCap":3270651387.12},{"date":"2024-04-12","current":24.173756,"twenty":30.404732,"median":36.432536,"eighty":45.004481,"marketCap":3078077137.88},{"date":"2024-04-19","current":24.609778,"twenty":29.677763,"median":36.289315,"eighty":44.938488,"marketCap":3127556802.58},{"date":"2024-04-26","current":25.396884,"twenty":29.011941,"median":36.169269,"eighty":44.868397,"marketCap":3239367008.29},{"date":"2024-05-03","current":25.125077,"twenty":28.84322,"median":36.062467,"eighty":44.633305,"marketCap":3203669221.23},{"date":"2024-05-10","current":26.025435,"twenty":28.633736,"median":35.997283,"eighty":44.566345,"marketCap":3323128791.91},{"date":"2024-05-17","current":23.786609,"twenty":28.457413,"median":35.841921,"eighty":44.342163,"marketCap":3384597470.53},{"date":"2024-05-24","current":21.936652,"twenty":28.195987,"median":35.701363,"eighty":44.23426,"marketCap":3102092113.2},{"date":"2024-05-31","current":21.435159,"twenty":27.970637,"median":35.598334,"eighty":44.222609,"marketCap":3039383806.02},{"date":"2024-06-07","current":22.690097,"twenty":27.463826,"median":35.382456,"eighty":43.895086,"marketCap":3211638521.11},{"date":"2024-06-14","current":22.285278,"twenty":26.048085,"median":35.173981,"eighty":43.895086,"marketCap":3139567043.35},{"date":"2024-06-21","current":21.323834,"twenty":25.875989,"median":34.8436,"eighty":43.864406,"marketCap":3015344623.92},{"date":"2024-06-28","current":22.482628,"twenty":25.849972,"median":34.751792,"eighty":43.843953,"marketCap":3180274284.27},{"date":"2024-07-05","current":21.972427,"twenty":25.639244,"median":34.657272,"eighty":43.651713,"marketCap":3127376247.29},{"date":"2024-07-12","current":22.998515,"twenty":25.494281,"median":34.422199,"eighty":43.533747,"marketCap":3270585876.4},{"date":"2024-07-15","current":22.953023,"twenty":25.430859,"median":34.413972,"eighty":43.516271,"marketCap":3254489261.98},{"date":"2024-08-02","current":20.309458,"twenty":25.403679,"median":34.373922,"eighty":43.501635,"marketCap":2841766295.19},{"date":"2024-08-09","current":20.723514,"twenty":25.129607,"median":34.224644,"eighty":43.440249,"marketCap":2735666122.5},{"date":"2024-08-16","current":19.860035,"twenty":24.796645,"median":34.162619,"eighty":43.405587,"marketCap":2630022203.9},{"date":"2024-08-23","current":19.838448,"twenty":24.268888,"median":33.920018,"eighty":43.283252,"marketCap":2645505418.49},{"date":"2024-08-30","current":19.471469,"twenty":23.8321,"median":33.734128,"eighty":43.147809,"marketCap":2621186477.04},{"date":"2024-09-06","current":18.602592,"twenty":23.494241,"median":33.671115,"eighty":43.072078,"marketCap":2495925620.93},{"date":"2024-09-13","current":19.185441,"twenty":22.907687,"median":33.604952,"eighty":43.042951,"marketCap":2560815499.76},{"date":"2024-09-20","current":20.831449,"twenty":22.803751,"median":33.570295,"eighty":43.028387,"marketCap":2786196948.41},{"date":"2024-09-27","current":21.948725,"twenty":22.594145,"median":33.45372,"eighty":42.744396,"marketCap":2956487278.6},{"date":"2024-10-04","current":21.646505,"twenty":22.472834,"median":33.3614,"eighty":42.700705,"marketCap":2900362552.24},{"date":"2024-10-11","current":21.560157,"twenty":22.285278,"median":33.233174,"eighty":42.591477,"marketCap":2843647655.11},{"date":"2024-10-18","current":22.617927,"twenty":22.261739,"median":32.698187,"eighty":42.533222,"marketCap":2977792893.11},{"date":"2024-10-25","current":22.645897,"twenty":22.285278,"median":31.73976,"eighty":42.511377,"marketCap":2967565955.08},{"date":"2024-10-31","current":23.088453,"twenty":22.329808,"median":31.05346,"eighty":42.505551,"marketCap":3006452868.32},{"date":"2024-11-08","current":30.478219,"twenty":22.389519,"median":30.568298,"eighty":42.486619,"marketCap":2853731574.85},{"date":"2024-11-15","current":30.530988,"twenty":22.401664,"median":30.478219,"eighty":42.476424,"marketCap":2830133907.78},{"date":"2024-11-22","current":30.757144,"twenty":22.402758,"median":30.568681,"eighty":42.451666,"marketCap":2862659955.58},{"date":"2024-11-29","current":33.961013,"twenty":22.434826,"median":30.673837,"eighty":42.419625,"marketCap":3148783777.17},{"date":"2024-12-06","current":34.669633,"twenty":22.46611,"median":30.907914,"eighty":42.257969,"marketCap":3210086264.85},{"date":"2024-12-13","current":33.207161,"twenty":22.47871,"median":31.108842,"eighty":42.148741,"marketCap":3040755582.89},{"date":"2024-12-20","current":31.48838,"twenty":22.488641,"median":31.48838,"eighty":42.00893,"marketCap":2849502272.41},{"date":"2024-12-27","current":33.734858,"twenty":22.494713,"median":31.970845,"eighty":41.91281,"marketCap":3041459063.87},{"date":"2025-01-03","current":33.410701,"twenty":22.507997,"median":32.326091,"eighty":41.867662,"marketCap":3006099952.21},{"date":"2025-01-10","current":30.583758,"twenty":22.548751,"median":32.187154,"eighty":41.739502,"marketCap":2758779888.76},{"date":"2025-01-17","current":28.714206,"twenty":22.594145,"median":31.76484,"eighty":41.57202,"marketCap":2591110278.91},{"date":"2025-01-24","current":30.922991,"twenty":22.613171,"median":31.446918,"eighty":40.977822,"marketCap":2794075415.08},{"date":"2025-01-31","current":29.754521,"twenty":22.627085,"median":31.164224,"eighty":40.788494,"marketCap":2682414705.78},{"date":"2025-02-07","current":44.52783,"twenty":22.642592,"median":31.108842,"eighty":40.977822,"marketCap":2778433490.84},{"date":"2025-02-14","current":46.096561,"twenty":22.681257,"median":31.405456,"eighty":41.965239,"marketCap":2894690862.79},{"date":"2025-02-21","current":45.29574,"twenty":22.741461,"median":31.73976,"eighty":42.419625,"marketCap":2847627453.27},{"date":"2025-02-28","current":46.79865,"twenty":22.792532,"median":32.079,"eighty":42.507008,"marketCap":2895255396.7},{"date":"2025-03-07","current":41.862084,"twenty":22.806185,"median":32.332694,"eighty":42.635168,"marketCap":2622361985.36},{"date":"2025-03-14","current":41.423278,"twenty":22.822194,"median":32.713389,"eighty":42.635168,"marketCap":2565848922.04},{"date":"2025-03-21","current":43.880591,"twenty":22.853037,"median":32.981006,"eighty":43.034213,"marketCap":2732813300.12},{"date":"2025-03-28","current":42.224099,"twenty":22.88278,"median":33.123373,"eighty":43.054602,"marketCap":2633489494.72},{"date":"2025-04-04","current":39.042756,"twenty":22.901877,"median":33.222238,"eighty":43.034213,"marketCap":2482102274.67},{"date":"2025-04-11","current":36.168577,"twenty":22.907687,"median":33.258379,"eighty":42.953904,"marketCap":2303349084},{"date":"2025-04-17","current":36.662234,"twenty":22.91307,"median":33.3614,"eighty":42.840307,"marketCap":2360722684.91},{"date":"2025-04-25","current":38.011562,"twenty":22.933896,"median":33.415912,"eighty":42.72692,"marketCap":2443342344.25}],"updateTime":1745910627351}}}